Table 1.
The distribution of demographic variables in the cohorts
| Total study population | Risk study for diabetes | Risk study for hemodialysis | |
|---|---|---|---|
| Number, N (%) | 20,686 | 13,310 | 20,205 |
| Mean ± SD age, years | 67.9 ± 13.2 | 67.7 ± 13.9 | 67.9 ± 13.2 |
| Gender, N (%) | |||
| Female | 9,922 (48.0%) | 6,760 (50.8%) | 9,748 (48.2%) |
| Male | 10,764 (52.0%) | 6,550 (49.2%) | 10,457 (51.8%) |
| In/outpatients, N (%) | |||
| Inpatients | 5,300 (25.6%) | 3,344 (25.1%) | 5,127 (25.4%) |
| Outpatients | 15,386 (74.4%) | 9,966 (74.9%) | 15,078 (74.6%) |
| Concomitant and previous diagnosis, N (%) | |||
| Diabetes | 7,083 (34.2%) | 0 (0.0%) | 6,798 (33.6%) |
| Hyperlipidemia | 7,247 (35.0%) | 3,662 (27.5%) | 7,083 (35.1%) |
| Cerebrovascular disease | 3,305 (16.0%) | 1,954 (14.7%) | 3,198 (15.8%) |
| Myocardial infarction | 757 (3.7%) | 275 (2.1%) | 733 (3.6%) |
| Angina pectoris | 6,757 (32.7%) | 3,555 (26.7%) | 6,504 (32.2%) |
| Cardiac failure | 4,196 (20.3%) | 2,188 (16.4%) | 3,935 (19.5%) |
| Renal disease | 2,099 (10.1%) | 971 (7.30%) | 1,670 (8.30%) |
| Hyperuricemia | 1,921 (9.3%) | 1,063 (8.0%) | 1,796 (8.9%) |
| Other macroangiopathy | 2,249 (10.9%) | 1,231 (9.2%) | 2,154 (10.7%) |
| Antihypertensive drug use at entered period, N (%) | |||
| ARB | 9,481 (45.8%) | 5,767 (43.3%) | 9,271 (45.9%) |
| CCB | 12,497 (60.4%) | 8,111 (60.9%) | 12,180 (60.3%) |
| ACE inhibitor | 2,140 (10.3%) | 1,300 (9.8%) | 2,112 (10.5%) |
| Other | 7,174 (34.7%) | 4,368 (32.8%) | 6,885 (34.1%) |
| Other concomitant use drug at registration, N (%) | |||
| Antidiabetic drug | 2,827 (13.7%) | 0 (0.0%) | 2,746 (13.6%) |
| Antihyperlipidemic drug | 4,684 (22.6%) | 2,498 (18.8%) | 4,639 (23.0%) |
| Antithrombotic or anticoagulant drug | 6,999 (33.8%) | 3,871 (29.1%) | 6,801 (33.7%) |
SD standard deviation, ARB angiotensin II receptor blocker, ACE inhibitor angiotensin-converting enzyme inhibitor, CCB calcium channel blocker